AIMS: To examine the relations between genetic loci, plasma lipoprotein(a) [Lp(a)] levels, and cardiovascular disease (CVD) risk among diabetic patients and compare with the observations in the general population. METHODS AND RESULTS: In two prospective cohorts of patients with type 2 diabetes (n= 2308) from the Nurses' Health Study and the Health Professional Follow-Up Study, we performed (i) genome-wide association (GWA) scans for plasma Lp(a); (ii) prospective analysis of plasma Lp(a) for CVD risk and mortality; and (iii) genetic association analysis for CVD risk and mortality. Meta-analysis of the two GWA scans yielded 71 single-nucleotide polymorphisms (SNPs) on chromosome 6q associated with plasma Lp(a) levels at a genome-wide significance level (P< 5 × 10(-8)). The SNP rs10455872 in LPA was most strongly associated with Lp(a) (P= 4.60 × 10(-39)). Forward-selection analysis indicated that rs10455872 and other five SNPs in a region encompassing LPA, PLG, SLC22A3, and LPAL2 genes were independently associated with Lp(a) levels and jointly explained ∼20% of variation in diabetic patients. In prospective analysis, we did not find any significant association between plasma levels and CVD incidence; the relative risk for coronary heart disease (CHD), CVD, and CVD death was 1.05 [95% confidence interval (CI): 0.95-1.15], 1.05 (0.96-1.15), and 1.21 (0.99-1.47) per 1-SD higher log-transformed Lp(a) levels, respectively. Consistently, none of the Lp(a) SNPs were associated with CVD risk or mortality (all P> 0.09). For the best SNP rs10455872 for plasma Lp(a) levels, the OR for CHD, CVD, and CVD death was 0.94 (95% CI: 0.69-1.28), 0.97 (0.72-1.29), and 1.23 (0.79-1.92), respectively. The genetic effect on CHD risk showed a significant heterogeneity between the diabetic and the general populations (P= 0.006). CONCLUSION: Our data indicate that the effect of Lp(a) on CVD risk among diabetic patients might be different from that in the general population. Diabetes status may attenuate the relation between Lp(a) and cardiovascular risk.
AIMS: To examine the relations between genetic loci, plasma lipoprotein(a) [Lp(a)] levels, and cardiovascular disease (CVD) risk among diabeticpatients and compare with the observations in the general population. METHODS AND RESULTS: In two prospective cohorts of patients with type 2 diabetes (n= 2308) from the Nurses' Health Study and the Health Professional Follow-Up Study, we performed (i) genome-wide association (GWA) scans for plasma Lp(a); (ii) prospective analysis of plasma Lp(a) for CVD risk and mortality; and (iii) genetic association analysis for CVD risk and mortality. Meta-analysis of the two GWA scans yielded 71 single-nucleotide polymorphisms (SNPs) on chromosome 6q associated with plasma Lp(a) levels at a genome-wide significance level (P< 5 × 10(-8)). The SNP rs10455872 in LPA was most strongly associated with Lp(a) (P= 4.60 × 10(-39)). Forward-selection analysis indicated that rs10455872 and other five SNPs in a region encompassing LPA, PLG, SLC22A3, and LPAL2 genes were independently associated with Lp(a) levels and jointly explained ∼20% of variation in diabeticpatients. In prospective analysis, we did not find any significant association between plasma levels and CVD incidence; the relative risk for coronary heart disease (CHD), CVD, and CVD death was 1.05 [95% confidence interval (CI): 0.95-1.15], 1.05 (0.96-1.15), and 1.21 (0.99-1.47) per 1-SD higher log-transformed Lp(a) levels, respectively. Consistently, none of the Lp(a) SNPs were associated with CVD risk or mortality (all P> 0.09). For the best SNP rs10455872 for plasma Lp(a) levels, the OR for CHD, CVD, and CVD death was 0.94 (95% CI: 0.69-1.28), 0.97 (0.72-1.29), and 1.23 (0.79-1.92), respectively. The genetic effect on CHD risk showed a significant heterogeneity between the diabetic and the general populations (P= 0.006). CONCLUSION: Our data indicate that the effect of Lp(a) on CVD risk among diabeticpatients might be different from that in the general population. Diabetes status may attenuate the relation between Lp(a) and cardiovascular risk.
Authors: Heinz Drexel; Stefan Aczel; Thomas Marte; Werner Benzer; Peter Langer; Willi Moll; Christoph H Saely Journal: Diabetes Care Date: 2005-01 Impact factor: 19.112
Authors: Christoph H Saely; Stefan Aczel; Thomas Marte; Peter Langer; Guenter Hoefle; Heinz Drexel Journal: J Clin Endocrinol Metab Date: 2005-08-09 Impact factor: 5.958
Authors: Karen A Matthews; Mary Fran Sowers; Carol A Derby; Evan Stein; Heidi Miracle-McMahill; Sybil L Crawford; Richard C Pasternak Journal: Am Heart J Date: 2005-06 Impact factor: 4.749
Authors: Lu Qi; Tricia Li; Eric Rimm; Cuilin Zhang; Nader Rifai; David Hunter; Alessandro Doria; Frank B Hu Journal: Diabetes Date: 2005-05 Impact factor: 9.461
Authors: Qianyi Ma; Ayse B Ozel; Shweta Ramdas; Beth McGee; Rami Khoriaty; David Siemieniak; Hong-Dong Li; Yuanfang Guan; Lawrence C Brody; James L Mills; Anne M Molloy; David Ginsburg; Jun Z Li; Karl C Desch Journal: Blood Date: 2014-09-10 Impact factor: 22.113
Authors: Yanglu Zhao; Joseph A Delaney; Ruben G W Quek; Julius M Gardin; Calvin H Hirsch; Shravanthi R Gandra; Nathan D Wong Journal: Clin Cardiol Date: 2016-05-13 Impact factor: 2.882